Gilde Healthcare supports national roll out of dental chain Tandarts Today - Gilde Healthcare

Gilde Healthcare supports national roll out of dental chain Tandarts Today

April 26, 2021

Utrecht and Eindhoven (the Netherlands) – Gilde Healthcare, a specialized healthcare investor with €1.4 billion under management, announces its investment in dental chain Tandarts Today. With this acquisition, Gilde Healthcare enters the Dutch Dental Care Market with its attractive market dynamics and prevailing growth opportunities.

Eindhoven-based Tandarts Today is an innovative emerging operator of dental clinics, providing high-quality care and a patient centric approach. The group offers the scale advantages of a large organization combined with the feeling of a local dental practice, distinguishing itself from competitors with its broad range of specialized services combined with small-scale implementation. These services provide valuable flexibility for dentists in clinical operations, which is typically limited within larger chains.

Gilde Healthcare’s investment will provide Tandarts Today with capital to further expand its market position and services in the domestic market, mainly through acquisitions, but also by investing in modern equipment and further digitization of the dental lab.

“We have been following the developments in the dental space for several years now. In Tandarts Today we have found the quality platform that we have been looking for. The strong track record and enthusiasm with which management continues to build a high-quality operator in this market has convinced us. We believe that this investment will drive improvements in the quality of dental care.”

says Hugo de Bruin, partner at Gilde Healthcare.

“We are delighted to welcome Gilde Healthcare as an investor in Tandarts Today. Gilde Healthcare will be a valuable partner for our growth plans due to its proven market expertise and experience in implementing buy-and-build strategies within the healthcare space. Our shared ambition is to grow Tandarts Today further and offer national coverage while maintaining an individual local approach,”

says Ruben Hoefnagels, CEO and Founder of Tandarts Today.

 

Media contacts:
LifeSci Advisors
Frank Schwarz – fschwarz@lifesciadvisors.com / +49 17 26 15 31 60
Gilde Healthcare
Hugo de Bruin – debruin@gildehealthcare.com / +31 30 219 2525

About Tandarts Today
Tandarts Today is a fast-growing chain of dental practices and dental laboratories with a distinctive character, based in Eindhoven, the Netherlands. Founded in 2015 by Ruben Hoefnagels, Tandarts Today has grown from one practice to running 10+ clinics and central labs with a focus on the south-east of The Netherlands. With a strong track record of growth, Tandarts Today provides a full service offering to patients across the organization while maintaining the personal touch and ambiance of the local clinics. Its success with patients is primarily based on trust and a positive relationship between patient and provider. https://www.tandartstoday.nl

About Gilde Healthcare
Gilde Healthcare is a specialized healthcare investor managing over €1.4 billion across two fund strategies: Private Equity and Venture & Growth. Gilde Healthcare Private Equity participates in profitable European lower mid-market healthcare companies with a prime focus on the Benelux and DACH region. The Private Equity fund targets healthcare providers, suppliers of medical products and service providers in the healthcare market. Gilde Healthcare Venture & Growth invests in medtech, healthtech and therapeutics in Europe and North America.
For more information, visit the company’s website at www.gildehealthcare.com.

Gilde Healthcare company Noema Pharma Announces First Patients Dosed in Phase 2b Study for Tourette Syndrome

Phase 2b study will evaluate the safety and efficacy of gemlapodect (NOE-105) in patients with Tourette syndrome Noema Pharma AG, a clinical-stage neuroscience-based company, today announced the first patients have been dosed in a global...
October 30, 2024

Gilde Healthcare invests in SynOx Therapeutics and company doses first patients in Phase 3 trial

Gilde Healthcare Leads Series B Extension, Joining Premier Syndicate of Leading Life Science Investors Funding Supports Registrational Phase 3 TANGENT Trial of Emactuzumab, a Best-in-Class CSF-1 Receptor Targeted Antibody, for the Treatment of Tenosynovial Giant...
October 30, 2024

Gilde Healthcare company Lumicks secures €20 Million from European investment bank to accelerate drug discovery

Amsterdam-based LUMICKS signs €20 million venture debt with EIB to accelerate the development and launch of its new product, designed to advance immunotherapy development for cancer research. LUMICKS’ next generation high-throughput cell avidity platform aims...
October 10, 2024